Evidence map›Paper›PMID 41074766›Full record

ArticleFuture medicinal chemistry2025

"Spiro-pyrrolizidine-benzyloxy hybrid as synergistic partner to doxorubicin cardio-safe breast cancer chemotherapy".

Uthirapathi Rajapandiyan, M Raj Kumar, H Manikandan, K Sivakumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Crystal structure and Hirshfeld surface analysis of 2-oxo-4-phenyl-2,5,6,7,8,9-hexa-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Uthirapathi RajapandiyanDepartment of Chemistry, Annamalai University, Chidambaram, India.
M Raj KumarDepartment of Chemistry, Annamalai University, Chidambaram, India.
H ManikandanDepartment of Chemistry, Annamalai University, Chidambaram, India.
K SivakumarDepartment of Chemistry, Sri Chandrasekharendra Saraswathi Viswa Mahavidyalaya (Deemed University), Kanchipuram, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE OF

objectiveThis study aims to develop novel spiro-pyrrolizidine-benzyloxy hybrids (RP

methodsSpiro-pyrrolizidine-benzyloxy hybrids (RP

resultsAmong the synthesized hybrids, RP

conclusionsCompounding RP

Indexed as

Antineoplastic AgentsBreast NeoplasmsDoxorubicinSpiro CompoundsCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorDrug SynergismFemaleHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsDoxorubicinSpiro Compoundsanticancerdoxorubicinhybrid compoundsMDA-MB-231Spiropyrrolizidinesynergism

Identifiers

PMID41074766
PMCPMC12582117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.